SLC5A2 and type 2 diabetes mellitus: The mechanism of benefit of SGLT2 inhibitors may involve glucose metabolism and/or lipid uptake to macrophages in a deranged glycaemic environment, but a glucose independent mechanism is not excluded, given the benefits seen in some studies of non-T2D rodents and in non-diabetic human clinical trials.